Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Abaloparatide (QLG2128) vs Teriparatide in Postmenopausal Osteoporosis
NCT06898060Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Peptides
01
Overview
Phase 3, randomised, open-label trial of abaloparatide in postmenopausal osteoporosis (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine at 52 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
abaloparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT06898060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898060.